Cargando…

EPI-X4, a novel endogenous antagonist of CXCR4

Detalles Bibliográficos
Autores principales:	Buske, Christian, Kirchhoff, Frank, Münch, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742086/ https://www.ncbi.nlm.nih.gov/pubmed/26459389

Ejemplares similares

Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström’s Macroglobulinemia
por: Kaiser, Lisa Marie, et al.
Publicado: (2021)

Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications
por: Gaonkar, Raghuvir Haridas, et al.
Publicado: (2023)

Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations
por: Gilg, Andrea, et al.
Publicado: (2021)

Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists
por: Sokkar, Pandian, et al.
Publicado: (2021)

Conformational States of the CXCR4 Inhibitor Peptide EPI-X4—A Theoretical Analysis
por: Jung, Christoph Karsten, et al.
Publicado: (2023)

Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability
por: Harms, Mirja, et al.
Publicado: (2023)

An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation
por: Harms, Mirja, et al.
Publicado: (2021)

CXCR4 antagonists for treatment of breast cancer
por: Cortés, Javier, et al.
Publicado: (2018)

CXCR4 antagonists in hematologic malignancies: more than just mobilizers?
por: Jo, Deog-Yeon
Publicado: (2011)

CXCR4 in Waldenström’s Macroglobulinema: chances and challenges
por: Kaiser, Lisa Marie, et al.
Publicado: (2020)

Calcineurin/CXCR4 in T-ALL
por: Passaro, Diana, et al.
Publicado: (2015)

Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists
por: Mishra, Rama K., et al.
Publicado: (2016)

CXCR4 as a novel target in immunology: moving away from typical antagonists
por: Caspar, Birgit, et al.
Publicado: (2022)

Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability
por: Rodríguez-Alfonso, Armando, et al.
Publicado: (2022)

The dynamic yin-yang interaction of CXCR4 and CXCR7 in breast cancer metastasis
por: Hawkins, Oriana E, et al.
Publicado: (2012)

Molecular basis for the antagonistic activity of an anti-CXCR4 antibody
por: Peng, Li, et al.
Publicado: (2015)

CCR5 and CXCR4 antagonist and agonist binding sites
por: Teintze, Martin, et al.
Publicado: (2006)

CXCR4 or CXCR7 antagonists treat endometriosis by reducing bone marrow cell trafficking
por: Pluchino, Nicola, et al.
Publicado: (2020)

A Novel CXCR4 antagonist enhances angiogenesis via modifying the ischaemic tissue environment
por: Yan, Xiaoqing, et al.
Publicado: (2017)

Synthesis and Anti-HIV Activity of a Novel Series of Isoquinoline-Based CXCR4 Antagonists
por: Shad, Mastaneh Safarnejad, et al.
Publicado: (2021)

Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists
por: Morimoto, Mamoru, et al.
Publicado: (2016)

A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment
por: Song, Jen-Shin, et al.
Publicado: (2021)

Fluorescent CXCR4 chemokine receptor antagonists: metal activated binding
por: Khan, Abid, et al.
Publicado: (2007)

CXCR4 antagonists suppress small cell lung cancer progression
por: Taromi, Sanaz, et al.
Publicado: (2016)

POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL
por: Sison, Edward Allan R., et al.
Publicado: (2015)

Discovery and Computer Aided Potency Optimization of a Novel Class of Small Molecule CXCR4 Antagonists
por: Vinader, Victoria, et al.
Publicado: (2013)

Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases
por: Portella, Luigi, et al.
Publicado: (2013)

Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist
por: Parameswaran, Reshmi, et al.
Publicado: (2011)

CXCL12-CXCR4 axis in feline mammary carcinoma
por: Ferreira, Fernando
Publicado: (2017)

Identification of Anti-Malarial Compounds as Novel Antagonists to Chemokine Receptor CXCR4 in Pancreatic Cancer Cells
por: Kim, Joseph, et al.
Publicado: (2012)

Establishment of a novel CCR5 and CXCR4 expressing CD4(+ )cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists
por: Princen, Katrien, et al.
Publicado: (2004)

Exploratory Studies on Development of the Chemokine Receptor CXCR4 Antagonists Toward Downsizing
por: Tamamura, Hirokazu, et al.
Publicado: (2008)

PET imaging of CXCR4 using copper-64 labeled peptide antagonist
por: Jacobson, Orit, et al.
Publicado: (2011)

Chemokine receptor CXCR4 oligomerization is disrupted selectively by the antagonist ligand IT1t
por: Ward, Richard J., et al.
Publicado: (2020)

Protective Effect of CXCR4 Antagonist CX807 in a Rat Model of Hemorrhagic Stroke
por: Yu, Seong-Jin, et al.
Publicado: (2020)

A novel small molecule CXCR4 antagonist potently mobilizes hematopoietic stem cells in mice and monkeys
por: Fang, Xiao, et al.
Publicado: (2021)

Small molecule CXCR4 antagonists block the HIV-1 Nef/CXCR4 axis and selectively initiate the apoptotic program in breast cancer cells
por: Huang, Ming-Bo, et al.
Publicado: (2018)

Spermine and spermidine bind CXCR4 and inhibit CXCR4- but not CCR5-tropic HIV-1 infection
por: Harms, Mirja, et al.
Publicado: (2023)

Differential effects of CXCR4 antagonists on the survival and proliferation of myeloid leukemia cells in vitro
por: Kim, Ha-Yon, et al.
Publicado: (2011)

CXCR4 Antagonist AMD3100 Accelerates Impaired Wound Healing in Diabetic Mice
por: Nishimura, Yukihide, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_39r962nsus3dvrrcgr504qs97v